The CEO of Arbutus (interim) describes the company's work in hepatitis B and highlights recent EASL data

blonca9
Jun 20, 2024
1 min read

Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for using a small molecule PD-L1 inhibitor against hepatitis B, and more.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

The CEO of Arbutus (interim) describes the company's work in hepatitis B and highlights recent EASL data

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight